Stocks Faring Away From Broker’s Choice: Teva Pharmaceutical Industries (NYSE:TEVA), AstraZeneca (NYSE:AZN)

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) [Trend Analysis] runs in leading trade, it plunging -7.53% to traded at $35.10. The firm has price volatility of 2.83% for a week and 2.26% for a month. Its beta stands at 0.60 times. Lets us look over what analysts have to say about performance of the TEVA. Starting with EPS for the final quarter of this year. EPS is usually the indicator of profitability for the company. According to WSJ analysis, the Q4 2016 current estimates trends were for $1.36 as compared to the next year Q1 current trend of $1.34. While on annual basis the current EPS estimates trend for FY 2017 came in for $5.40 as compared to three months ago $5.46.

The stock prices target chart showed high target of 100.01 kept by analysts at WSJ while the average price target was for 50.96 as compared to current price of 35.10. Somehow, the stock managed to gain BUY ratings by 16 analysts in current tenure as 2 analysts having overweight ratings, 12 recommend as HOLD, 0 stands at Underweight. Overall, the consensus ratings were for Overweight by the pool of analysts.

Narrow down four to firm performance, its weekly performance was -2.72% and monthly performance was 0.20%. The stock price of TEVA is moving down from its 20 days moving average with -4.27% and isolated negatively from 50 days moving average with -8.18%.

AstraZeneca PLC (NYSE:AZN) [Trend Analysis] luring active investment momentum, shares a loss -0.91% to $28.43. Finally to see some strong financial remarks by WSJ over AZN performance. Out of the pool of analysts 17 gave their BUY ratings on the stock in previous month as 19 analysts having BUY in current month. The 3 analysts gave SELL rank. Majority ranked Overweight from the pool of analysts.

The next year first quarter EPS estimates trend for current period shows $0.59 while one month ago this estimate trend was for $0.59. EPS indicator shows the robustness of the stock and its analysis opens up the clear picture of company’s profitability. On annual basis of EPS, FY 2017 Estimate Trends at current were for $1.92 and for the one month was for $1.92 as compared to three months ago was for $2.04. Whereas, AZN received highest price target of 40.48 and low target of 24.31. The stock price target chart showed average price target of 32.31 as compared to current price of 28.43.

The total volume of 6.06 Million shares held in the session was surprisingly higher than its average volume of 7336.71 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 128.90%, and looking further price to next year’s EPS is -10.90%. While take a short look on price to sales ratio, that was 3.02 and price to earnings ratio of 29.19 attracting passive investors.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *